Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22428716 | 0.96 | ALOX5 (0.36) | ALOX5PTGS1PTGS2TDP1ALDH1A1 | |
| SCHEMBL24995534 | 0.82 | ALOX5 (0.35) | ALOX5PTGS1PTGS2KIF11 | |
| SCHEMBL26549674 | 0.81 | ALOX5 (0.35) | ALOX5PTGS1PTGS2KIF11 | |
| SCHEMBL1705592 | 0.78 | KIF11 (0.39) | ALOX5PTGS1PTGS2TDP1ALDH1A1 | |
| SCHEMBL13412862 | 0.76 | ALOX5 (0.36) | ALOX5PTGS1PTGS2KIF11CA2 | |
| SCHEMBL21150744 | 0.74 | TDP1 (0.35) | TDP1ALDH1A1TSHRCA2HTT | |
| SCHEMBL18235336 | 0.72 | KIF11 (0.35) | ALOX5PTGS1PTGS2ALDH1A1KIF11 | |
| SCHEMBL12341054 | 0.71 | LATS1 (0.40) | ALOX5PTGS1PTGS2ALDH1A1KIF11 | |
| SCHEMBL12680655 | 0.71 | ALDH1A1 (0.46) | TDP1ALDH1A1TSHRKIF11CA2 | |
| SCHEMBL24622864 | 0.70 | TAAR1 (0.35) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | ALOX5 3148/4885PTGS1 822/4885PTGS2 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.